ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. - Wikidata - wikimedia - TriplyDB

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

http://www.wikidata.org/entity/Q35763908

about

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Androgen receptor (AR) in cardiovascular diseases Targeting molecular resistance in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Emerging data on androgen receptor splice variants in prostate cancer Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.Splicing variants of androgen receptor in prostate cancer.Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer 20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.Methylselenocysteine preventing castration-resistant progression of prostate cancer AR Pathway Is Involved in the Regulation of CX43 in Prostate Cancer.ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.Cancer subclonal genetic architecture as a key to personalized medicine.Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.Androgen receptor roles in the development of benign prostate hyperplasia On the origins of the androgen receptor low molecular weight species.Targeting the androgen receptor in prostate cancer.Androgen receptor splice variants in the era of enzalutamide and abiraterone.Decoding the androgen receptor splice variants.Leading causes of castration-resistant prostate cancer.Are androgen receptor variants a substitute for the full-length receptor?Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals.Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential.Drug discovery in advanced prostate cancer: translating biology into therapy.

P2860

Q26750620-4F753CFB-DFD1-4CCA-BCD7-FEB70030D6EA Q26771962-8AEAA824-74E4-47CF-967A-133038B7D0B4 Q26795445-7B2525EC-F57B-46CB-9DA3-6742D1C82D12 Q26796704-978BD868-A930-4450-A2F1-DE121E211AE6 Q26858922-A7284BF6-91B5-4429-9CC6-829EBEDE6CEB Q28077830-93D67349-A643-4ED1-9B47-68F2931F3645 Q28539233-E59260B8-81F3-4565-BC5F-05B554599148 Q30528764-C27F6752-4539-4ED4-91C0-3CB6292016BF Q33688956-DE2D3893-47FE-4044-BC1B-D4C6762A8FEE Q33842431-79B6D632-B0AC-459D-8187-824587E3427B Q34448143-B2A94A12-EAD0-413D-AF6C-7602ED6B0347 Q34663140-ECE5762B-FD70-48BB-B12C-E252A168B10B Q35399276-447D8564-135C-4FAD-AF23-9673E8B90F43 Q35582612-E395776F-93CB-4229-AF82-A66AF870AE75 Q36146251-8AE7C962-5CBE-4755-9212-DED2D9170D01 Q36283346-7527A414-1F67-426D-93D9-E522E2DE04A3 Q36298863-B94CA592-F541-4132-9623-B6A2D7C1ECA4 Q36413827-D7901AE7-90A2-4E9F-AD49-C42A51C15C1F Q36450795-B3F2D9C1-B4E9-4E79-9195-A21FE27FC712 Q36544528-6A544D8C-C330-4A3E-864A-8BC56896EBC1 Q36582853-D7ED3B2A-10B9-4BB1-B347-AF07B173814C Q37000514-E77C7BAA-FF0B-47C1-AA71-5D045B595291 Q37322621-10B99488-8368-4759-934D-437731F4B588 Q37376793-C6E5DF3B-D367-4BEF-AC8D-E004B93A550E Q37448116-945238BE-4F47-4F91-91CF-3B36466C98B2 Q37488488-7DD98CAC-2A14-4E13-A2EF-67EE75E4CA9D Q37687068-D6EEAA08-BED6-4D83-B20D-7C1814758038 Q38097574-5E49D575-B3E8-4B85-8A67-B90FCA6B8F9D Q38122085-23F91FA2-A5AF-47B3-96BA-7FC0EF5A4DC0 Q38217060-47343A5F-2ED5-47C5-A66F-1D27A99B48B7 Q38232413-CACD5003-51FB-4108-A6DF-6C0FAEB42960 Q38263870-BC2D45C5-06D3-4CB0-BA24-4752811F5B51 Q38341864-66D5B57D-F598-4285-B39B-5B1B92C9B773 Q38350089-0D192564-5931-48CC-BD8E-69DF0D9D4B7C Q38361928-CBE8BE67-9902-4FE0-A170-277EB51105DC Q38681329-2726070D-2186-4C6A-9E48-25B7125588E1 Q38743727-7E4EDCF6-ED0B-4FF3-A9A4-5A8D2F715BBD Q38769921-F8C2D31C-D692-4AB1-AB94-69B629BC01B7 Q38780353-37936677-1F5D-4DA3-BAC1-E45B69F8D107 Q38839110-0DC5DE1A-35D0-401D-8EFF-D19EC84C620B

P2860

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

http://www.wikidata.org/entity/Q35763908

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@ast

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@en

type

label

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@ast

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@en

prefLabel

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@ast

ASC-J9 suppresses castration-r ...... ce variant androgen receptors.

@en

P1433

Q35763908-7E99DB20-0B6E-457B-B222-88554519103B

P1476

Q35763908-0F2C4393-8015-47BA-B302-C1377FBC8177

P2093

Q35763908-063C174C-6CF3-4DCE-86B6-A49E1CB5B912

Q35763908-0B8514C4-3664-4497-B6EB-02AD0721EC8D

Q35763908-26564421-53F9-4EBF-AE0B-37543C145CC9

Q35763908-26B33BE5-7E58-4F1D-86B7-25024A488F4C

Q35763908-3A759495-DC4D-4103-A8D1-549C219A0C34

Q35763908-83C454C4-3F08-48D4-B7E9-F74A8DE8C047

Q35763908-D68B1A07-4B40-4A47-91D2-0E83287C2083

Q35763908-D91474B1-F969-4B07-9D91-B49998B455EC

Q35763908-ECBCB67B-0BC5-44A5-ADC1-F304A9FFC451

Q35763908-EF7C3802-B5F6-43DD-A9D3-A2420490BAFF

P2860

Q35763908-15BF4057-F9F8-4C6F-AE85-FD6C93A37428

Q35763908-1AB427C1-7D0E-4741-B2F3-549A547F31DA

Q35763908-20EABDAD-5C29-4329-BE6C-2A294DE7A9CD

Q35763908-2E9C99D4-D5C7-44CC-B244-690DA8ABA327

Q35763908-318EFDA2-5610-4850-BD99-DC2A2A94FD8C

Q35763908-353B695A-0B4E-4039-BC6B-3822420A12CD

Q35763908-6A520B5A-580D-498A-9432-EEC875C8665B

Q35763908-7C0135AC-AAE7-460F-88CC-67833060F714

Q35763908-83583237-8599-484F-8978-580A9A088F07

Q35763908-8DB6D7E6-3840-44B1-B86D-E4D043774E2B

P304

Q35763908-0630F432-2F1A-4420-AD29-9EF73A18D8EE

P31

Q35763908-B0C6AD7B-4EE0-41FB-86D7-BDD141F26729

P356

Q35763908-7A0BA6B4-79F8-47C0-9C1B-9E350D6BCD99

P433

Q35763908-A8D3A230-D7F1-4B1B-9FBC-3FB748229019

P478

Q35763908-D5413EBF-D7A0-4A94-90BD-DB37AAF851C1

P50

Q35763908-5A5A9A15-C478-4685-A1DD-F840BD3FD333

P577

Q35763908-B0DEC8B0-F8C6-43AF-97F7-4C613919B3FD

P698

Q35763908-69B5E048-B1AE-45D3-B3DF-D98C0F0FAD5B

P932

Q35763908-D361E09A-A001-4C76-B2C3-083B36F4D812

P356

P1433

P1476

ASC-J9 suppresses castration-r ...... ice variant androgen receptors

@en

P2093

Chawnshang Chang

http://www.w3.org/2001/XMLSchema#string

Defeng Xu

http://www.w3.org/2001/XMLSchema#string

Hsing-Jien Kung

http://www.w3.org/2001/XMLSchema#string

Kun-Lung Chuang

http://www.w3.org/2001/XMLSchema#string

Kuo-Pao Lai

http://www.w3.org/2001/XMLSchema#string

Lei Li

http://www.w3.org/2001/XMLSchema#string

See-Tong Pang

http://www.w3.org/2001/XMLSchema#string

Shinichi Yamashita

http://www.w3.org/2001/XMLSchema#string

Shuyuan Yeh

http://www.w3.org/2001/XMLSchema#string

Tatsuo Tochigi

http://www.w3.org/2001/XMLSchema#string

P2860

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

Cancer statistics, 2010

Molecular cloning of human and rat complementary DNA encoding androgen receptors

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Molecular determinants of resistance to antiandrogen therapy

Androgen receptor in prostate cancer

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

P304

74-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.111436

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Hiroshi Miyamoto

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22355276

http://www.w3.org/2001/XMLSchema#string

P932

3281944

http://www.w3.org/2001/XMLSchema#string